You are here

The Effect of Disease Activity on Birth Outcomes in a Nationwide Cohort of Women with Moderate to Severe Inflammatory Bowel Disease.

The Effect of Disease Activity on Birth Outcomes in a Nationwide Cohort of Women with Moderate to Severe Inflammatory Bowel Disease. Inflamm Bowel Dis. 2017 Mar 24;: Authors: Kammerlander H, Nielsen J, Kjeldsen J, Knudsen T, Friedman S, Nørgård B Abstract BACKGROUND: Active inflammatory bowel disease (IBD) during conception and pregnancy may increase the risk of adverse birth outcomes. Former studies have examined heterogeneous groups of women with varying degrees of IBD severity. We aimed to examine the effect of active IBD on birth outcomes in a more homogeneous group…

Read More

Preoperative Extraintestinal Manifestations Associated with Chronic Pouchitis in Japanese Patients with Ulcerative Colitis After Ileal Pouch-anal Anastomosis: A Retrospective Study.

Preoperative Extraintestinal Manifestations Associated with Chronic Pouchitis in Japanese Patients with Ulcerative Colitis After Ileal Pouch-anal Anastomosis: A Retrospective Study. Inflamm Bowel Dis. 2017 Mar 24;: Authors: Hata K, Ishii H, Anzai H, Ishihara S, Nozawa H, Kawai K, Kiyomatsu T, Watanabe T Abstract BACKGROUND: Pouchitis is a major problem after ileal pouch-anal anastomosis in patients with ulcerative colitis. Chronic pouchitis is particularly troublesome. This study aimed to identify risk factors for the development of chronic pouchitis in a Japanese population. METHODS: We retrospectively reviewed 100 patients who underwent pouchoscopy…

Read More

Treatment Persistence for Infliximab Versus Adalimumab in Crohn’s Disease: A 14-Year Single-Center Experience.

Treatment Persistence for Infliximab Versus Adalimumab in Crohn’s Disease: A 14-Year Single-Center Experience. Inflamm Bowel Dis. 2017 Mar 16;: Authors: Olivera P, Thiriet L, Luc A, Baumann C, Danese S, Peyrin-Biroulet L Abstract BACKGROUND: Infliximab (IFX) and adalimumab (ADA) are widely used in the treatment of patients with Crohn’s disease (CD). There are few published data on the treatment persistence of IFX and ADA in patients with CD. METHODS: We aimed to compare the persistence rates of IFX versus ADA as first- and second-line tumor necrosis factor antagonist (anti-TNF), to…

Read More

Ocular Involvement in Children with Inflammatory Bowel Disease.

Ocular Involvement in Children with Inflammatory Bowel Disease. Inflamm Bowel Dis. 2017 Mar 21;: Authors: Naviglio S, Parentin F, Nider S, Rassu N, Martelossi S, Ventura A Abstract BACKGROUND: Data on ocular manifestations of inflammatory bowel disease (IBD) in children are limited. Some authors have reported a high prevalence of asymptomatic uveitis, yet the significance of these observations is unknown and there are no recommendations on which ophthalmologic follow-up should be offered. METHODS: Children with IBD seen at a single referral center for pediatric gastroenterology were offered ophthalmologic evaluation as…

Read More

Long-term Maintenance of Clinical, Endoscopic, and Radiographic Response to Ustekinumab in Moderate-to-Severe Crohn’s Disease: Real-world Experience from a Multicenter Cohort Study.

Long-term Maintenance of Clinical, Endoscopic, and Radiographic Response to Ustekinumab in Moderate-to-Severe Crohn’s Disease: Real-world Experience from a Multicenter Cohort Study. Inflamm Bowel Dis. 2017 Mar 21;: Authors: Ma C, Fedorak RN, Kaplan GG, Dieleman LA, Devlin SM, Stern N, Kroeker KI, Seow CH, Leung Y, Novak KL, Halloran BP, Huang VW, Wong K, Blustein PK, Ghosh S, Panaccione R Abstract BACKGROUND: Ustekinumab is a monoclonal antibody targeting interleukins 12 and 23. While effective in clinical trials for Crohn’s disease (CD), long-term maintenance of response in the real-world setting is…

Read More

A Novel User-Friendly Model to Predict Corticosteroid Utilization in Newly Diagnosed Patients with Ulcerative Colitis.

A Novel User-Friendly Model to Predict Corticosteroid Utilization in Newly Diagnosed Patients with Ulcerative Colitis. Inflamm Bowel Dis. 2017 Mar 21;: Authors: Khan N, Patel D, Shah Y, Lichtenstein G, Yang YX Abstract BACKGROUND: Corticosteroid (CS) use is an important marker of poor prognosis in ulcerative colitis (UC). Our aim was to develop and validate a model to predict the risk of CS utilization over the course of disease in newly diagnosed patients with UC. METHODS: Newly diagnosed patients with UC from a nationwide VA cohort were followed over time…

Read More

Quality of Care and Outcomes Among Hospitalized Inflammatory Bowel Disease Patients: A Multicenter Retrospective Study.

Quality of Care and Outcomes Among Hospitalized Inflammatory Bowel Disease Patients: A Multicenter Retrospective Study. Inflamm Bowel Dis. 2017 Mar 21;: Authors: Nguyen GC, Murthy SK, Bressler B, Lam MC, Alali A, Toumi A, Reinglas J, Rampersad A, Weizman AV, Afif W, CINERGI group Abstract BACKGROUND: Half of patients with inflammatory bowel disease (IBD) require hospitalization. We sought to characterize inpatient quality indicators of care and outcomes during IBD-related hospitalizations at 4 major IBD referral centers in Canada. METHODS: We conducted a multicenter retrospective cohort study of patients with IBD…

Read More

Etiopathogenesis of Nephrolithiasis in Ulcerative Colitis Patients with the Ileal Pouch Anal Anastomosis.

Etiopathogenesis of Nephrolithiasis in Ulcerative Colitis Patients with the Ileal Pouch Anal Anastomosis. Inflamm Bowel Dis. 2017 Mar 15;: Authors: Arora Z, Mukewar S, Lopez R, Camino D, Shen B, Hall P Abstract BACKGROUND: Our previous study showed that nephrolithiasis is a common complication in ulcerative colitis patients after ileal pouch anal anastomosis (IPAA). However, the pathogenesis of nephrolithiasis in IPAA patients has not been studied. The aim of this study was to compare urine and serum metabolic compositions in IPAA patients with nephrolithiasis and controls with IPAA and no…

Read More
<< Go Back